Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

SPL-026 is under development for the treatment of major depressive disorder (MDD). The drug candidate is a psychedelic N,N-dimethyltryptamine (DMT) based medicine. It is administered through i ...

Medically reviewed by Dakari Quimby, PhD Male postpartum depression describes when a new father experiences postpartum ...

Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to huge impacts on direct and indirect personal and public medical costs. To overcome such a serious mental ...

Clinics offering ketamine infusions and injections for “treatment-resistant depression” are today claiming 24-48 hours ...

But one state has disability coverage parity, in which mental health conditions are covered in the same way as physical health conditions: Vermont. The U.S. passed its first federal health parity law ...

ITI-1284 is under clinical development by Intra-Cellular Therapies and currently in Phase II for Generalized Anxiety Disorder (GAD).

Symptoms of depression begin in late spring to early summer. This type is much less common. Depression often happens with other conditions, such as heart disease or cancer. It may also happen with ...

Discover why psychiatrists are moving beyond single-treatment approaches and how combining therapies could be the key to ...

17, 2024 — Almost three quarters of adolescents in Australia experience clinically significant depression or anxiety symptoms ... a 'Lifesaving' Drug for Major Depression, Alleviate Symptoms ...

Diagnoses of PTSD and anxiety disorders nearly doubled between 2019 and 2023, according to a new Defense Health Agency report ...

Disability carriers have continued to avoid parity, which has translated to people paying billions of dollars out of pocket ...